Elsevier

Gynecologic Oncology

Volume 72, Issue 3, March 1999, Pages 337-341
Gynecologic Oncology

Regular Article
Failure to Demonstrate Human Papillomavirus DNA in Epithelial Ovarian Cancer by General Primer PCR

https://doi.org/10.1006/gyno.1998.5264Get rights and content

Abstract

One of the recent controversies with substantial clinical interest is the role of HPV in pathogenesis of ovarian cancer. The available highly conflicting data are based on analysis of 175 ovarian carcinomas so far. As an attempt to further elucidate this issue, the first systematic study of HPV detection in ovarian cancer was carried out using a highly sensitive general primer PCR (confirmed by hybridization for low- and high-risk HPV types separately) in a series of 98 histologically and clinically well-characterized epithelial ovarian malignancies. Despite the high (fg) sensitivity and a wide HPV type coverage of the technique used, all 98 ovarian carcinomas failed to demonstrate any signs of HPV DNA whatsoever. The preexisting 12 reports comprising a total of 175 ovarian tumors analyzed for HPV were summarized, giving highly discrepant results (i.e., detection rates from 0 to 100%) with the overall HPV DNA detection rate of 25.7%. The reasons for these discrepant findings are most probably technical. Our data are consistent with those of the majority of the most recent reports failing to disclose HPV DNA in ovarian neoplasia. The present completely negative results make the authors inclined to conclude that HPV is highly unlikely to play any causal role in the pathogenesis of epithelial ovarian neoplasia.

References (30)

  • E Franco et al.

    New Developments in Cervical Cancer Screening and Prevention

    (1997)
  • CH Lai et al.

    Human papillomavirus in benign and malignant ovarian and endometrial tissues

    Int J Gynecol Pathol

    (1992)
  • MA Duggan et al.

    Uterine atypical polypoid adenomyoma and ovarian endometrioid carcinoma. Metastatic disease or dual primers

    Int J Gynecol Pathol

    (1995)
  • A-M Trottier et al.

    Absence of human papillomavirus sequences in ovarian pathologies

    J Clin Microbiol

    (1995)
  • Cited by (67)

    • Human papillomavirus and ovarian cancer (review of literature and meta-analysis)

      2021, Infection, Genetics and Evolution
      Citation Excerpt :

      A high variability in the prevalence of the virus from 0% (Kaufman et al., 1987) to 83.3% (McLellan et al., 1990) was shown. In the studies over the next decade, the results also vary in a significant range from 0% (Bosch, 2011; Beckmann et al., 1991; Trottier et al., 1995; Anttilaa et al., 1999; Chen et al., 1999) to 66.7% (Lai et al., 1994). Currently, more sensitive methods are used.

    • Ovarian cancer

      2014, The Lancet
    • Persistent oral human papillomavirus infection is associated with smoking and elevated salivary immunoglobulin G concentration

      2014, Journal of Clinical Virology
      Citation Excerpt :

      HPV-DNA was extracted from the scrapings with the high salt method [25]. The first HPV-testing for the presence of any high risk HPVs was performed using nested PCR with MY09/MY11 as external and GP05+/GP06+ as internal primers and hybridisation of the PCR products with a digoxigenin-labelled HR-HPV-oligoprobe cocktail [26,27]. Next, HPV genotyping was performed with a Multimetrix kit® (Multimetrix, Progen Biotechnik GmbH, Heidelberg, Germany) detecting 24 low risk (6, 11, 42, 43, 44, and 70) and high risk (16, 18, 26, 31, 33, 35, 39, 45, 51, 52, 53, 56, 58, 59, 66, 68, 73 and 82) HPV-genotypes.

    • Oral mucosa as a reservoir of human papillomavirus: Point prevalence, genotype distribution, and incident infections among males in a 7-year prospective study

      2012, European Urology
      Citation Excerpt :

      HPV testing was done with a nested polymerase chain reaction (PCR) using MY09 and MY11 as external primers and GP05+/GP06+ as internal primers [21]. The PCR products were first hybridised with a digoxigenin-labelled high-risk HPV oligoprobe cocktail (HPV types 16, 18, 31, 33, 35, 39, 45, 51, 52, 54, 56, and 58) to determine whether the samples were high-risk HPV positive or negative [22]. The PCR products available from previous high-risk HPV positive or negative testing were used for HPV genotyping with the Multimetrix kit (Progen Biotechnik, Heidelberg, Germany).

    View all citing articles on Scopus

    Becker, YDarai, G

    View full text